Oncology Med Acquisition on Track -- Set to Acquire Medical/Radiation Company Which Has Gross Revenues of $2,800,000.00
29 Abril 2008 - 8:35AM
Marketwired
PITTSBURGH, PA , a Pittsburgh based cancer treatment solutions
group, announced today that the acquisition candidate announced at
the end of January, 2008 has passed its due diligence inquiry and
has entered the contract stage with a synergistic company in the
field of physics and radiation that has annual revenues of
$2,800,000.00, operates on a national scale, and is profitable.
According to William Walker, Ph.D., Oncology Med's CEO and
founder, "We are extremely excited exiting the due diligence period
and expect to have definitive agreements in place for this
acquisition within the next 30 - 45 days. Although we originally
stated that the acquisition would close in May, 2008 we now expect
the closing to occur in the 3rd quarter of 2008. The company is a
leader in their field and presents many cross marketing
opportunities for us. We believe this will be one of many
acquisitions that we will pursue. As previously mentioned, our plan
is to take advantage of our organic growth in addition to exciting
and accretive acquisitions."
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of
services related to the treatment of various cancers. It currently
provides analysis and design of radiation treatment plans in order
for radiation oncologists to administer radiation treatments to
cancer patients. Current services facilitate radiation treatment
programs ranging from external beam radiation to more advanced
radiation treatment technologies.
More information about Oncology Med, Inc. can be found at
www.oncologymed.com.
NOTE: This press release may contain "forward-looking
statements." In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue" or the negative of
such terms and other comparable terminology. These forward-looking
statements include, without limitation, statements about our market
opportunity, our strategies, competition, expected activities and
expenditures as we pursue our business plan, and the adequacy of
our available cash resources. Although we believe that the
expectations reflected in any forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Actual results may differ materially
from the predictions discussed in these forward-looking statements.
Changes in the circumstances upon which we base our predictions
and/or forward-looking statements could materially affect our
actual results.
For information, please contact: William Walker, Ph.D. Oncology
Med, Inc. Email Contact
Bellatora (PK) (USOTC:ECGR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Bellatora (PK) (USOTC:ECGR)
Gráfica de Acción Histórica
De May 2023 a May 2024